Ethical Considerations during the Informed Consent Process for Acute Ischemic Stroke in International Clinical Trials

Area of Science:

• Neurology
• Clinical Trials
• Medical Ethics

Background:

• Active-control trials in acute ischemic stroke compare new therapies against tissue plasminogen activator (tPA).
• The informed consent process is critical but presents challenges in these time-sensitive trials.
• Understanding researcher experiences is key to optimizing consent procedures.

Purpose of the Study:

• To investigate researcher experiences with informed consent in acute ischemic stroke trials.
• To identify approaches and challenges in obtaining informed consent.
• To evaluate the impact of consent processes on door-to-treatment times.

Main Methods:

• Systematic review of 401 articles to identify 14 relevant active-control trials.
• Survey of trial representatives regarding their informed consent procedures.
• Analysis of the relationship between consent methods and door-to-treatment times.

Main Results:

• None of the 14 trials published details on their informed consent process.
• Trials with higher direct consent rates (75-100%) showed shorter door-to-treatment times.
• Trials utilizing translators and translated documents had longer door-to-treatment times.

Conclusions:

• International variations in informed consent standards may permit more direct consent without delaying treatment.
• Transparency in the informed consent process is crucial for future acute ischemic stroke trials.
• Optimizing consent procedures can improve patient access to time-critical interventions.